National Antimicrobial Resistance Monitoring System using Retail Meat for Louisiana

NARMS加强和加强抗生素合作协议计划 零售食品样品的耐药性监测 机构资助机会编号：PA-20-124 路易斯安那州 2020年7月1日-2021年6月30日 摘要 该项目将包括顺利完成采购，加工和 每月检测48个肉类和海鲜样本。身份证EPI将识别、收集和 在FDA和NARMS的时间限制内处理样品。身份证的三个人 EPI致力于及时收集和提交数据。 增加和改进了对特定的抗菌素耐药性数据的分析 路易斯安那州，将受到审查的趋势和关系，用来更好地告知 机构和公众，并研究制定缓解和/或预防政策。 这些活动将展示国家卫生部门在 保护和改善公众健康。 增加更多的目标生物和改进实验室技术， 例如将全基因组测序扩展到更多的生物体，将允许 更高质量的信息和更强的识别相关病例或疫情的能力 过去、现在和未来。该计划将促进与FDA的协调 和其他机构参与疫情调查。该计划还将提供高质量 FDA NARMS计划可以使用的零售肉类和海鲜监测数据 其他州的数据。质量数据的这种增长可以用来影响政策 关于抗菌剂的使用、耐药性和耐药性趋势。

NARMS Cooperative Agreement Program to Enhance and Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens Agency Funding Opportunity Number: PA-20-124 Louisiana 7/1/2020-6/30/2021 Abstract This project will involve the successful completion of the purchasing, processing, and testing of 48 meat and seafood samples per month. ID Epi will identify, collect and process samples within the FDA's and NARMS time constraints. Three persons from ID Epi are dedicated to timely collections and submissions. The increase in and improved analysis of antimicrobial resistance data specific to Louisiana, will be scrutinized for trends and relationships, used to better inform the agency and the public, and studied to develop policies for mitigation and/or prevention. These activities will demonstrate the importance of the state health department in protecting and improving the public's health. The addition of additional target organisms and improvement of laboratory techniques, such as the extension of whole genome sequencing to additional organisms, will permit higher quality information and increased ability to identify related cases or outbreaks in the past, at present, and in the future. The program will facilitate coordination with FDA and other agencies in investigations of outbreaks. The program will also provide quality retail meat and seafood surveillance data the FDA NARMS program can use in addition to other states' data. This increase in quality data can be used to influence policy regarding antimicrobial use, resistance and trends in resistance.